Rui Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rui Liang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Anguo Zhao
Department of Urology South China Hospital Medical School Shenzhen University Shenzhen 518116 P. R. China
1 shared publicationDaitian Tang
Department of Urology South China Hospital Medical School Shenzhen University Shenzhen 518116 P. R. China
1 shared publicationDashi Deng
Department of Urology South China Hospital Medical School Shenzhen University Shenzhen 518116 P. R. China
1 shared publication- Lei Peng
Department of Urology South China Hospital Medical School Shenzhen University Shenzhen China
1 shared publication Qi Zhuang
Department of Urology South China Hospital Medical School Shenzhen University Shenzhen 518116 P. R. China
1 shared publicationRongkang Li
Department of Urology Lanzhou University Second Hospital Lanzhou 730000 P. R. China
1 shared publication
Latest Publications
- Open Access
- 26 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (25) , e2502750
Self‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy
Bladder cancer, a common malignancy of the urinary tract, presents complex therapeutic challenges, thereby necessitating the exploration of innovative treatment strategies. This study introduces a novel, self‐propelled nanomedicine delivery system that forms nanoparticles within the bladder lumen by co‐infusing dopamine hydrochloride, Mn 2+ , cGAMP, and urease into the bladder to initiate in situ polymerization. The resulting Mn‐cGAMP@PDA‐urease (DMCU) nanoparticles possess a urease‐modified surface, which acts as an engine to generate propulsive force by breaking down urea. Consequently, this process enhances nanoparticle retention in the bladder mucosa and facilitates efficient drug delivery. The self‐assembled nanoparticles activate the STING pathway, promoting dendritic cell maturation and activation of T cells, thereby enhancing anti‐tumor immune responses. These nanoparticles remain in the bladder for an extended period, significantly improving therapeutic efficacy by sustaining drug release and reducing adverse side effects. In vivo, experiments using a mouse orthotopic model of bladder cancer demonstrate that the DMCU system enhances tumor suppression and immune activation compared with conventional therapies. This novel approach integrates nanotechnology with immunomodulation to address chemotherapy resistance and improve therapeutic efficacy.
- 26 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (25) , e2502750
Open AccessSelf‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy
Bladder cancer, a common malignancy of the urinary tract, presents complex therapeutic challenges, thereby necessitating the exploration of innovative treatment strategies. This study introduces a novel, self‐propelled nanomedicine delivery system that forms nanoparticles within the bladder lumen by co‐infusing dopamine hydrochloride, Mn 2+ , cGAMP, and urease into the bladder to initiate in situ polymerization. The resulting Mn‐cGAMP@PDA‐urease (DMCU) nanoparticles possess a urease‐modified surface, which acts as an engine to generate propulsive force by breaking down urea. Consequently, this process enhances nanoparticle retention in the bladder mucosa and facilitates efficient drug delivery. The self‐assembled nanoparticles activate the STING pathway, promoting dendritic cell maturation and activation of T cells, thereby enhancing anti‐tumor immune responses. These nanoparticles remain in the bladder for an extended period, significantly improving therapeutic efficacy by sustaining drug release and reducing adverse side effects. In vivo, experiments using a mouse orthotopic model of bladder cancer demonstrate that the DMCU system enhances tumor suppression and immune activation compared with conventional therapies. This novel approach integrates nanotechnology with immunomodulation to address chemotherapy resistance and improve therapeutic efficacy.